Endocannabinoid system as a potential mechanism for n-3 long-chain polyunsaturated fatty acid mediated cardiovascular protection

Proceedings of the Nutrition Society

Volumn 72, Issue 4, 2013, Pages 460-469

  Wainwright, Cherry L ^a   Michel, Lisa ^a  

^a ROBERT GORDON UNIVERSITY   (United Kingdom)

Author keywords

Arrhythmia; Atherosclerosis; Cardioprotection; Endocannabinoids; Hypertension; n 3 LC PUFA

Indexed keywords

CALCIUM CHANNEL L TYPE; CANNABINOID RECEPTOR; ENDOCANNABINOID; LONG CHAIN FATTY ACID; N 3 LONG CHAIN POLYUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DIACYLGLYCEROL; G PROTEIN COUPLED RECEPTOR; LIPOPROTEIN LIPASE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE A1; PHOSPHOLIPASE C BETA;

ACUTE HEART INFARCTION; ANTIARRHYTHMIC ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE; CONFERENCE PAPER; CONJUGATE; HEART ARRHYTHMIA; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; REPERFUSION INJURY; ANTIINFLAMMATORY ACTIVITY; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CORRELATION ANALYSIS; DIET THERAPY; HEART MUSCLE ISCHEMIA; LIPID DIET; LIPOGENESIS; TISSUE LEVEL;

CARDIOVASCULAR DISEASES; ENDOCANNABINOIDS; FATTY ACIDS, OMEGA-3; HEART; HUMANS; INFLAMMATION;

EID: 84893045849     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665113003406     Document Type: Conference Paper

References (110)

1. Montecucco F & Di Marzo V (2012) At the heart of the matter: The endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 33, 331-340.
2. Matsuda LA, Lolait SJ, Brownstein MJ, et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564.
3. Munro S, Thomas KL & Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65.
4. Batkai S, Pacher P, Osei-Hyiaman D, et al. (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110, 1996-2002.
5. Pacher P, Batkai S & Kunos G (2005) Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 168, 599-625.
6. Gebremedhin D, Lange AR, Narayanan J, et al. (1998) Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-Type Ca2+ current. J Physiol 507, Pt 3, 771-781.
7. Daly CJ, Ross RA, Whyte J, et al. (2010) Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol 159, 787-796.
8. Nam DH, Lee MH, Kim JE, et al. (2012) Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 153, 1387-1396.
9. Defer N, Wan J, Souktani R, et al. (2009) The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/ reperfusion-induced cardiomyopathy. FASEB J 23, 2120-2130.
10. Rajesh M, Mukhopadhyay P, Batkai S, et al. (2007) CB2-receptor stimulation attenuates TNF-Alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293, H2210-H2218.
11. Zygmunt PM, Petersson J, Andersson DA, et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457.
12. Pertwee RG (2007) GPR55: A new member of the cannabinoid receptor clan? Br J Pharmacol 152, 984-986.
13. Hiley CR (2009) Endocannabinoids and the heart. J Cardiovasc Pharmacol 53, 267-276.
14. Di Marzo V, Fontana A, Cadas H, et al. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
15. Sun YX, Tsuboi K, Okamoto Y, et al. (2004) Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J 380, Pt 3, 749-756.
16. Kondo S, Kondo H, Nakane S, et al. (1998) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: Identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through CA2+-dependent and -independent mechanisms. FEBS Lett 429, 152-156.
17. Muccioli GG (2010) Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 15, 474-483.
18. Pertwee RG & Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66, 101-121.
19. Berger C, Schmid PC, Schabitz WR, et al. (2004) Massive accumulation of N-Acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88, 1159-1167.
20. Kurabayashi M, Takeyoshi I, Yoshinari D, et al. (2005) 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. J Invest Surg 18, 25-31.
21. Wagner JA, Hu K, Bauersachs J, et al. (2001) Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 38, 2048-2054.
22. Weis F, Beiras-Fernandez A, Sodian R, et al. (2010) Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J Mol Cell Cardiol 48, 1187-1193.
23. Rajesh M, Batkai S, Kechrid M, et al. (2012) Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 61, 716-727.
24. Sugamura K, Sugiyama S, Nozaki T, et al. (2009) Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119, 28-36.
25. Quercioli A, Pataky Z, Vincenti G, et al. (2011) Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 32, 1369-1378.
26. Adkins Y & Kelley DS (2010) Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem 21, 781-792.
27. Jung UJ, Torrejon C, Tighe AP, et al. (2008) n-3 fatty acids and cardiovascular disease: Mechanisms underlying beneficial effects. Am J Clin Nutr 87, 2003S-2009S.
28. De Caterina R & Zampolli A (2007) Omega-3 fatty acids, atherogenesis, and endothelial activation. J Cardiovasc Med 8, Suppl. 1, S11-S14.
29. Stanley WC, Khairallah RJ & Dabkowski ER (2012) Update on lipids and mitochondrial function: Impact of dietary n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 15, 122-126.
30. Meijerink J, Balvers M & Witkamp R (2013) N-Acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids-from fishy endocannabinoids to potential leads. Br J Pharmacol 169, 772-783.
31. Kim J, Li Y & Watkins BA (2013) Fat to treat fat: Emerging relationship between dietary PUFA, endocannabinoids, and obesity. Prostaglandins Other Lipid Mediat 104-105, 32-41.
32. Berger A, Crozier G, Bisogno T, et al. (2001) Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-Acylethanolamines in piglets. Proc Natl Acad Sci U S A 98, 6402-6406.
33. Wood JT, Williams JS, Pandarinathan L, et al. (2010) Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res 51, 1416-1423.
34. Watanabe S, Doshi M & Hamazaki T (2003) n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-Arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69, 51-59.
35. Batetta B, Griinari M, Carta G, et al. (2009) Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 139, 1495-1501.
36. Piscitelli F, Carta G, Bisogno T, et al. (2011) Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab 8, 51-7075-8-51.
37. Rossmeisl M, Jilkova ZM, Kuda O, et al. (2012) Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: Possible role of endocannabinoids. PloS ONE 7, e38834.
38. Varga K, Lake KD, Huangfu D, et al. (1996) Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 28, 682-686.
39. Lake KD, Martin BR, Kunos G, et al. (1997) Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29, 1204-1210.
40. Pacher P, Batkai S, Osei-Hyiaman D, et al. (2005) Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol. 289, H533-H541.
41. Jarai Z, Wagner JA, Varga K, et al. (1999) Cannabinoidinduced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96, 14136-14141.
42. Malinowska B, Baranowska-Kuczko M & Schlicker E (2012) Triphasic blood pressure responses to cannabinoids: Do we understand the mechanism? Br J Pharmacol 165, 2073-2088.
43. Varga K, Lake K, Martin BR, et al. (1995) Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278, 279-283.
44. Wagner JA, Varga K, Ellis EF, et al. (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518-521.
45. Cabo J, Alonso R & Mata P (2012) Omega-3 fatty acids and blood pressure. Br J Nutr 107, Suppl. 2, S195-200.
46. Cicero AF, Derosa G, Di Gregori V, et al. (2010) Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: A retrospective study. Clin Exp Hypertens 32, 137-144.
47. Russo C, Olivieri O, Girelli D, et al. (1995) Omega-3 polyunsaturated fatty acid supplements and ambulatory blood pressure monitoring parameters in patients with mild essential hypertension. J Hypertension 13, 12 Pt 2, 1823-1826.
48. Malinowska B, Kwolek G & Gothert M (2001) Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 364, 562-569.
49. McCollum L, Howlett AC & Mukhopadhyay S (2007) Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 321, 930-937.
50. Cicero AF, Ertek S & Borghi C (2009) Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management. Curr Vasc Pharmacol 7, 330-337.
51. Omura M, Kobayashi S, Mizukami Y, et al. (2001) Eicosapentaenoic acid (EPA) induces Ca(2+)-independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. FEBS Lett 487, 361-366.
52. Singh TU, Kathirvel K, Choudhury S, et al. (2010) Eicosapentaenoic acid-induced endothelium-dependent and -independent relaxation of sheep pulmonary artery. Eur J Pharmacol 636, 108-113.
53. Sanders TA, Hall WL, Maniou Z, et al. (2011) Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: A randomized controlled trial. Am J Clin Nutr 94, 973-980.
54. Skulas-Ray AC, Kris-Etherton PM, Harris WS, et al. (2011) Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 93, 243-252.
55. Woodman RJ, Mori TA, Burke V, et al. (2003) Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 166, 85-93.
56. Mackay I, Ford I, Thies F, et al. (2012) Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease. Atherosclerosis 221, 514-520.
57. Stirban A, Nandrean S, Gotting C, et al. (2010) Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr 91, 808-813.
58. Steffens S, Veillard NR, Arnaud C, et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786.
59. Rajesh M, Mukhopadhyay P, Hasko G, et al. (2008) CB2 cannabinoid receptor agonists attenuate TNF-Alphainduced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 153, 347-357.
60. Germain N, Boichot E, Advenier C, et al. (2002) Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-Alpha production by human mononuclear cells. Int Immunopharmacol 2, 537-543.
61. Willecke F, Zeschky K, Ortiz Rodriguez A, et al. (2011) Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. PloS ONE 6, e19405.
62. Dol-Gleizes F, Paumelle R, Visentin V, et al. (2009) Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 29, 12-18.
63. Rajesh M, Mukhopadhyay P, Hasko G, et al. (2008) Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun 377, 1248-1252.
64. Rajesh M, Mukhopadhyay P, Batkai S, et al. (2007) CB2-receptor stimulation attenuates TNF-Alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293, H2210-H2218.
65. Burr ML, Fehily AM, Gilbert JF, et al. (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 2, 757-761.
66. GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447-455.
67. Yokoyama M, Origasa H, Matsuzaki M, et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098.
68. von Schacky C, Angerer P, Kothny W, et al. (1999) The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 130, 554-562.
69. Sekikawa A, Curb JD, Ueshima H, et al. (2008) Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: A crosssectional study. J Am College Cardiol 52, 417-424.
70. Baumann KH, Hessel F, Larass I, et al. (1999) Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Arterioscler Thromb Vasc Biol 19, 59-66.
71. Wang TM, Chen CJ, Lee TS, et al. (2011) Docosahexaenoic acid attenuates VCAM-1 expression and NF-kappaB activation in TNF-Alpha-Treated human aortic endothelial cells. J Nutr Biochem 22, 187-194.
72. Thies F, Garry JM, Yaqoob P, et al. (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 361, 477-485.
73. Cawood AL, Ding R, Napper FL, et al. (2010) Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 212, 252-259.
74. Matsumoto M, Sata M, Fukuda D, et al. (2008) Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis 197, 524-533.
75. Wang PF, Jiang LS, Bu J, et al. (2012) Cannabinoid-2 receptor activation protects against infarct and ischemiareperfusion heart injury. J Cardiovasc Pharmacol 59, 301-307.
76. Pacher P & Hasko G (2008) Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 153, 252-262.
77. Tuma RF & Steffens S (2012) Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury. Curr Pharm Biotechnol 13, 46-58.
78. Underdown NJ, Hiley CR & Ford WR (2005) Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 146, 809-816.
79. Lepicier P, Bouchard JF, Lagneux C, et al. (2003) Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 139, 805-815.
80. Mukhopadhyay P, Horvath B, Rajesh M, et al. (2011) Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 50, 179-195.
81. Wagner JA, Abesser M, Harvey-White J, et al. (2006) 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J Cardiovasc Pharmacol 47, 650-655.
82. Bouchard JF, Lepicier P & Lamontagne D (2003) Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 72, 1859-1870.
83. Hajrasouliha AR, Tavakoli S, Ghasemi M, et al. (2008) Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur J Pharmacol 579, 246-252.
84. Montecucco F, Lenglet S, Braunersreuther V, et al. (2009) CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol 46, 612-620.
85. Landmark K, Abdelnoor M, Urdal P, et al. (1998) Use of fish oils appears to reduce infarct size as estimated from peak creatine kinase and lactate dehydrogenase activities. Cardiology 89, 94-102.
86. Zhu BQ, Sievers RE, Sun YP, et al. (1994) Is the reduction of myocardial infarct size by dietary fish oil the result of altered platelet function? Am Heart J 127, 4 Pt 1, 744-755.
87. Ogita H, Node K, Asanuma H, et al. (2003) Eicosapentaenoic acid reduces myocardial injury induced by ischemia and reperfusion in rabbit hearts. J Cardiovasc Pharmacol 41, 964-969.
88. Hlavackova M, Neckar J, Jezkova J, et al. (2007) Dietary polyunsaturated fatty acids alter myocardial protein kinase C expression and affect cardioprotection induced by chronic hypoxia. Exp Biol Med 232, 823-832.
89. O'Shea KM, Khairallah RJ, Sparagna GC, et al. (2009) Dietary omega-3 fatty acids alter cardiac mitochondrial phospholipid composition and delay Ca2+-induced permeability transition. J Mol Cell Cardiol 47, 819-827.
90. Abdukeyum GG, Owen AJ & McLennan PL (2008) Dietary (n-3) long-chain polyunsaturated fatty acids inhibit ischemia and reperfusion arrhythmias and infarction in rat heart not enhanced by ischemic preconditioning. J Nutr 138, 1902-1909.
91. McGuinness J, Neilan TG, Sharkasi A, et al. (2006) Myocardial protection using an omega-3 fatty acid infusion: Quantification and mechanism of action. J Thorac Cardiovasc Surg 132, 72-79.
92. Li Q, Shi M & Li B (2013) Anandamide enhances expression of heat shock protein 72 to protect against ischemia-reperfusion injury in rat heart. J Physiol Sci 63, 47-53.
93. Fosshaug LE, Berge RK, Beitnes JO, et al. (2011) Krill oil attenuates left ventricular dilatation after myocardial infarction in rats. Lipids Health Dis 10, 245-511X-10-245.
94. Lepicier P, Bibeau-Poirier A, Lagneux C, et al. (2006) Signaling pathways involved in the cardioprotective effects of cannabinoids. J Pharmacol Sci 102, 155-166.
95. Rao JS, Ertley RN, DeMar JC Jr, et al. (2007) Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol Psychiatry 12, 151-157.
96. Xue H, Wan M, Song D, et al. (2006) Eicosapentaenoic acid and docosahexaenoic acid modulate mitogenactivated protein kinase activity in endothelium. Vasc Pharmacol 44, 434-439.
97. Denys A, Hichami A & Khan NA (2002) Eicosapentaenoic acid and docosahexaenoic acid modulate MAP kinase enzyme activity in human T-cells. Mol Cell Biochem 232, 143-148.
98. Radosinska J, Bacova B, Bernatova I, et al. (2011) Myocardial NOS activity and connexin-43 expression in untreated and omega-3 fatty acids-Treated spontaneously hypertensive and hereditary hypertriglyceridemic rats. Mol Cell Biochem 347, 163-173.
99. Krylatov AV, Ugdyzhekova DS, Bernatskaya NA, et al. (2001) Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 131, 523-525.
100. Krylatov AV, Uzhachenko RV, Maslov LN, et al. (2002) Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: A possible mechanism. Bull Exp Biol Meds 133, 122-124.
101. Matthan NR, Jordan H, Chung M, et al. (2005) A systematic review and meta-Analysis of the impact of omega-3 fatty acids on selected arrhythmia outcomes in animal models. Metabolism 54, 1557-1565.
102. Den Ruijter HM, Berecki G, Opthof T, et al. (2007) Proand antiarrhythmic properties of a diet rich in fish oil. Cardiovasc Res 73, 316-325.
103. Li Q, Ma HJ, Zhang H, et al. (2009) Electrophysiological effects of anandamide on rat myocardium. Br J Pharmacol 158, 2022-2029.
104. Currie S, Rainbow RD, Ewart MA, et al. (2008) IP(3) R-mediated Ca(2+) release is modulated by anandamide in isolated cardiac nuclei. J Mol Cell Cardiol 45, 804-811.
105. Li Q, Ma HJ, Song SL, et al. (2012) Effects of anandamide on potassium channels in rat ventricular myocytes: A suppression of I(to) and augmentation of K(ATP) channels. Am J Phys. Cell Physiol. 302, C924-C930.
106. Kurihara J, Nishigaki M, Suzuki S, et al. (2001) 2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves. Japanese J Pharmacol 87, 93-96.
107. Du XJ, Dart AM & Riemersma RA (1993) Lack of modulation by dietary unsaturated fats on sympathetic neurotransmission in rat hearts. Am J Physiol 265, 3 Pt 2, H886-H892.
108. Yang R, Fredman G, Krishnamoorthy S, et al. (2011) Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J Biol Chem 286, 31532-31541.
109. Anagnostopoulos D, Rakiec C, Wood J, et al. (2010) Identification of endocannabinoids and related N-Acylethanolamines in tetrahymena. A new class of compounds for tetrahymena. Protist 161, 452-465.
110. Meijerink J, Plastina P, Vincken JP, et al. (2011) The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: Evidence for a new link between fish oil and inflammation. Br J Nutr 105, 1-10.